Sydney Cell and Gene Therapy
Sydney Cell and Gene Therapy (SCGT) provides a suite of clean-rooms based on Good Manufacturing Practice (GMP) and access to some of the world’s leading clinicians and medical researchers in cell and gene-based therapeutics.
The SCGT facilities and expertise are commercially available to the international biologics sector.
Our clean-rooms include aseptic and aseptic/biocontained, gene and cellular therapeutics manufacturing suites, supported by a GMP-based quality system.
SCGT is located within the modern Westmead Health Precinct, a short drive or train trip from Central Sydney.
SCGT is a joint venture of translational researchers involved in clinical trials in the areas of T-cell immunotherapy, islet transplantation and gene therapy.
Latest News
Professor Ian Alexander invited to present in Geneva
Prof. Ian Alexander was invited to speak at the SSIEM (Society for the Study of Inborn Errors of Metabolism) Conference held in Geneva, Switzerland (30 August 2011 – 2 September 2011). Prof Alexander presented an overview of gene therapy for metabolic disorders especially ornithine-transcarbamylase deficiency. When 30/Aug/2011 04:23 PM Where Details The aim of the…
Key stakeholders in cell and gene therapies meet in Singapore
Our Quality Manager, Richard Makin, attended the Phacilitate Cell and Gene Therapy Forum in Singapore on 19-21 September 2011. The forum focused on the commercial opportunities and challenges (regulatory and political) in the emerging Asian and Australia markets. A number of novel research and commercial products were showcased including preventive and regenerative therapies. Key…
SCGT provide technical expertise in cellular therapy accreditations
1/10/2011 In addition to working hard to maintain NATA and FACT accreditation a number of key SCGT staff have donated their time in 2012 to provide technical expertise to the accreditation bodies in assessments of other cellular therapy facilities. For a number of years our staff have assisted as NATA technical assessors. In 2012, we…